Case report: map2k1 k57n mutation is associated with primary resistance to anti-egfr monoclonal antibodies in metastatic colorectal cancer

HIGHLIGHTS

• who: Gianluca Mauri from the Innsbruck Medical University, Austria have published the article: Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer, in the Journal: (JOURNAL)
• what: The authors provide a molecular tumor board (MTB) discussion of two emblematic cases of uncommon MAP2K1 K57N mutated mCRC patients, commenting upon treatment decision making focused on anti-EGFR drug administration.

SUMMARY

After the identification of microsatellite stable (MSS), RAS and BRAF WT, MAP2K1 mutant mCRC, the authors retrospectively reviewed patients` records to evaluate . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.